R&D News | pharmaphorum

News

Gilead strikes again, penning $5bn deal to buy Tubulis

Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.

News

AI giant Anthropic buys Coefficient Bio for $400m

Anthropic has continued its push into the healthcare sector by acquiring New York start-up Coefficient Bio.

News

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.

News

Amgen scientists working in the lab, one woman and one man

Amgen scores with new thyroid eye disease formulation

Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?

News

Ambrosia's sweet $100m round, and other biofinancings

Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.

News

Immunovant's thyroid eye disease drug flunks pivotal trials

Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.

Gilead strikes again, penning $5bn deal to buy Tubulis

AI giant Anthropic buys Coefficient Bio for $400m

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Amgen scores with new thyroid eye disease formulation

Ambrosia's sweet $100m round, and other biofinancings

Immunovant's thyroid eye disease drug flunks pivotal trials

ESMO26: Lily's sofe-m ADC stakes a claim in ovarian cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks